Penumbra Inc (NYSE: PEN), a global healthcare company focused on innovative therapies, announced on Tuesday that it has named Jason Mills as its new executive vice president, Strategy.
Prior to joining Penumbra, Mills had served Canaccord Genuity as managing director and head of the medical technology equity research practice over a long term.
Mills said, 'I am elated to join Penumbra, excited to immerse myself in its robust culture, and committed to help in every way possible to augment Penumbra's dedication to the development of innovative therapies. I am grateful for the opportunity to contribute to this amazing team and company and to Penumbra's mission to do work that matters to physicians, patients, and their families.'
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business